TCTR20240811003已完成不适用
Safety and immunogenicity of COVID-19 vaccines for SARS-CoV-2 in lung cancer patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. age 18 years or above
- •2. Has an appointment to receive COVID-19 vaccine
- •3. Confirmed diagnosis of lung cancer by pathology or cytology
- •4. Life expectancy is more than 6 months at the time receiving first
排除标准
- •1. Previously diagnosed COVID-19 in the past 90 days
- •2. High-risk epidemiology history within 14 days before enrolment e.g. close contact with index cases or visiting/ living in outbreak area
- •3. Receive only one dose of COVID-19 vaccine
- •4. Receive blood products, blood components, or immunoglobulin within the past 90 days
- •5. Receive live attenuated vaccine in the past 28 days
- •6. Receive inactivated or subunit vaccines in the past 14 days
- •7. Women in lactation, pregnancy, or planned pregnancy during the study period
- •8. Known allergy to any vaccine component
- •9. Has signs and symptoms of active skin infection at injection site
- •10.Known history of HIV infection
- •11. Has uncontrolled medical illness that include cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological disease
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety of COVID-19 vaccines in SLE and rheumatoid arthritis patientsSLERAImmunosuppresive agentsImmunogenicity to SARS-CoV2 vaccinationSLEImmunosuppressive therapyHumoral immune responseCellular immune responseSARS-CoV-2 vaccineRATCTR20210917003Ratchadapiseksompotch Fund, Faculty of Medicine100
尚未招募
不适用
Immunogenicity and safety COVID-19 vaccine in healthy adults: a single institute based cohort studyCOVID-19JPRN-UMIN000043589Saga University60
已完成
4 期
The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplantNL-OMON51071niversitair Medisch Centrum Groningen850
进行中（未招募）
1 期
The efficacy and safety of COVID-19 vaccination in patients with a kidney diseaseCOVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccination would be of great clinical importance in these patients.However, SARS-CoV-2 vaccination studies have excluded KTR and patients with CKD so-far. This will be the subject of this trial.MedDRA version: 20.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10061105Term: DialysisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10084462Term: SARS-CoV-2 vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084463Term: SARS-CoV-2 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-000868-30-NLRECOVAC consortium850
招募中
4 期
The safety and efficacy of COVID-19 vaccines among lung transplant recipientslung transplant recipientslung transplant, solid organ transplant, COVID-19JPRN-jRCT1021210009Okada Yoshinori80